Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
6 hedge funds and large institutions have $162K invested in Therapix Biosciences Ltd. in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
286% more capital invested
Capital invested by funds: $42K → $162K (+$120K)
50% more funds holding
Funds holding: 4 → 6 (+2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$111K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.3K |
| 3 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$295 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.58K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$388 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TDC
1
Thompson Davis & Co
Richmond,
Virginia
| $120K | +$111K | +28,634 | New |
|
|
2
Morgan Stanley
New York
| $34K | -$6.58K | -1,697 | -18% |
|
|
3
UBS Group
Zurich,
Switzerland
| $7K | +$4.3K | +1,109 | +234% |
|
|
PA
4
Parallel Advisors
San Francisco,
California
| $1K | – | – | – |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| – | -$388 | -100 | -53% |
|
|
SWP
6
Stratos Wealth Partners
Beachwood,
Ohio
| – | +$295 | +76 | New |
|
TRPX Hedge Fund Activity: Q3 2018 in Review
6 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q3 2018, worth a combined $162K — up 286% from $42K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TRPX positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Thompson Davis & Co, opening a new position worth an estimated $111K. The largest seller was Morgan Stanley, cutting an estimated $6.58K.
- 6 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q3 2018, up from 4 in Q2 2018.
- Funds reported $162K of Therapix Biosciences Ltd. stock for Q3 2018, up 286% quarter-over-quarter.
- 2 funds opened new Therapix Biosciences Ltd. positions in Q3 2018 and 0 closed out, a net change of +2 holders.
- The largest Therapix Biosciences Ltd. buyer in Q3 2018 was Thompson Davis & Co, an estimated $111K added.
- The largest Therapix Biosciences Ltd. seller in Q3 2018 was Morgan Stanley, an estimated $6.58K sold.
Based on aggregated 13F filings for Q3 2018.